4zqk: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.== | ==Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.== | ||
<StructureSection load='4zqk' size='340' side='right' caption='[[4zqk]], [[Resolution|resolution]] 2.45Å' scene=''> | <StructureSection load='4zqk' size='340' side='right'caption='[[4zqk]], [[Resolution|resolution]] 2.45Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4zqk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZQK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZQK FirstGlance]. <br> | <table><tr><td colspan='2'>[[4zqk]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZQK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZQK FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zqk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zqk OCA], [http://pdbe.org/4zqk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zqk RCSB], [http://www.ebi.ac.uk/pdbsum/4zqk PDBsum]</span></td></tr> | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), PDCD1, PD1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zqk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zqk OCA], [http://pdbe.org/4zqk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zqk RCSB], [http://www.ebi.ac.uk/pdbsum/4zqk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4zqk ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 26: | Line 28: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Dubin, G]] | [[Category: Dubin, G]] | ||
[[Category: Holak, T A]] | [[Category: Holak, T A]] |
Revision as of 11:30, 26 June 2019
Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.
Structural highlights
Disease[PDCD1_HUMAN] Systemic lupus erythematosus;Multiple sclerosis. Systemic lupus erythematosus 2 (SLEB2) [MIM:605218]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.[1] Function[PD1L1_HUMAN] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.[2] [3] [PDCD1_HUMAN] Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.[4] Publication Abstract from PubMedTargeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has recently provided breakthrough progress in the treatment of melanoma, non-small cell lung cancer, and other types of cancer. Small-molecule drugs interfering with this pathway are highly awaited, but their development is hindered by insufficient structural information. This study reveals the molecular details of the human PD-1/PD-L1 interaction based on an X-ray structure of the complex. First, it is shown that the ligand binding to human PD-1 is associated with significant plasticity within the receptor. Second, a detailed molecular map of the interaction surface is provided, allowing definition of the regions within both interacting partners that may likely be targeted by small molecules. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.,Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Domling A, Dubin G, Holak TA Structure. 2015 Oct 22. pii: S0969-2126(15)00402-5. doi:, 10.1016/j.str.2015.09.010. PMID:26602187[5] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|